Cargando…

Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors

OBJECTIVES: To summarize data supporting the effects of antidiabetes agents on glucose control and cardiovascular risk factors in patients with type 2 diabetes. METHODS: Studies reporting on the effects of antidiabetes agents on glycemic control, body weight, lipid levels, and blood pressure paramet...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurukulasuriya, L Romayne, Sowers, James R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940872/
https://www.ncbi.nlm.nih.gov/pubmed/20804556
http://dx.doi.org/10.1186/1475-2840-9-45
_version_ 1782186858593124352
author Kurukulasuriya, L Romayne
Sowers, James R
author_facet Kurukulasuriya, L Romayne
Sowers, James R
author_sort Kurukulasuriya, L Romayne
collection PubMed
description OBJECTIVES: To summarize data supporting the effects of antidiabetes agents on glucose control and cardiovascular risk factors in patients with type 2 diabetes. METHODS: Studies reporting on the effects of antidiabetes agents on glycemic control, body weight, lipid levels, and blood pressure parameters are reviewed and summarized for the purpose of selecting optimal therapeutic regimens for patients with type 2 diabetes. RESULTS: National guidelines recommend the aggressive management of cardiovascular risk factors in patients with type 2 diabetes, including weight loss and achieving lipid and blood pressure treatment goals. All antidiabetes pharmacotherapies lower glucose; however, effects on cardiovascular risk factors vary greatly among agents. While thiazolidinediones, sulfonylureas, and insulin are associated with weight gain, dipeptidyl peptidase-4 inhibitors are considered weight neutral and metformin can be weight neutral or associated with a small weight loss. Glucagon-like peptide-1 receptor agonists and amylinomimetics (e.g. pramlintide) result in weight loss. Additionally, metformin, thiazolidinediones, insulin, and glucagon-like peptide-1 receptor agonists have demonstrated beneficial effects on lipid and blood pressure parameters. CONCLUSION: Management of the cardiovascular risk factors experienced by patients with type 2 diabetes requires a multidisciplinary approach with implementation of treatment strategies to achieve not only glycemic goals but to improve and/or correct the underlying cardiovascular risk factors.
format Text
id pubmed-2940872
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29408722010-09-17 Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors Kurukulasuriya, L Romayne Sowers, James R Cardiovasc Diabetol Review OBJECTIVES: To summarize data supporting the effects of antidiabetes agents on glucose control and cardiovascular risk factors in patients with type 2 diabetes. METHODS: Studies reporting on the effects of antidiabetes agents on glycemic control, body weight, lipid levels, and blood pressure parameters are reviewed and summarized for the purpose of selecting optimal therapeutic regimens for patients with type 2 diabetes. RESULTS: National guidelines recommend the aggressive management of cardiovascular risk factors in patients with type 2 diabetes, including weight loss and achieving lipid and blood pressure treatment goals. All antidiabetes pharmacotherapies lower glucose; however, effects on cardiovascular risk factors vary greatly among agents. While thiazolidinediones, sulfonylureas, and insulin are associated with weight gain, dipeptidyl peptidase-4 inhibitors are considered weight neutral and metformin can be weight neutral or associated with a small weight loss. Glucagon-like peptide-1 receptor agonists and amylinomimetics (e.g. pramlintide) result in weight loss. Additionally, metformin, thiazolidinediones, insulin, and glucagon-like peptide-1 receptor agonists have demonstrated beneficial effects on lipid and blood pressure parameters. CONCLUSION: Management of the cardiovascular risk factors experienced by patients with type 2 diabetes requires a multidisciplinary approach with implementation of treatment strategies to achieve not only glycemic goals but to improve and/or correct the underlying cardiovascular risk factors. BioMed Central 2010-08-30 /pmc/articles/PMC2940872/ /pubmed/20804556 http://dx.doi.org/10.1186/1475-2840-9-45 Text en Copyright ©2010 Kurukulasuriya and Sowers; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Kurukulasuriya, L Romayne
Sowers, James R
Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors
title Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors
title_full Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors
title_fullStr Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors
title_full_unstemmed Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors
title_short Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors
title_sort therapies for type 2 diabetes: lowering hba1c and associated cardiovascular risk factors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940872/
https://www.ncbi.nlm.nih.gov/pubmed/20804556
http://dx.doi.org/10.1186/1475-2840-9-45
work_keys_str_mv AT kurukulasuriyalromayne therapiesfortype2diabetesloweringhba1candassociatedcardiovascularriskfactors
AT sowersjamesr therapiesfortype2diabetesloweringhba1candassociatedcardiovascularriskfactors